Fluzopril plus Apatinib for platinum-resistant ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests two oral medications (Fluzopril and Apatinib) as a maintenance treatment to keep ovarian cancer from growing after initial chemotherapy. It is for women whose cancer returned within 6 months of platinum-based chemo, and who are currently stable after their last chemo cycle.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with advanced ovarian, fallopian tube, or primary peritoneal cancer (a specific type called high-grade serous or endometrioid adenocarcinoma).
- Your cancer got worse within 6 months after your last platinum-containing chemotherapy (like carboplatin or cisplatin).
- You have had at least 3 rounds of chemotherapy and are not currently getting worse after your last treatment.
- You must be able to provide a sample of your tumor from a past biopsy or surgery (a tissue block or slide).
- Your blood counts and organ function (kidney, liver) must meet certain levels, and you cannot have uncontrolled high blood pressure or major bleeding issues.
- You have not taken both a PARP inhibitor and a VEGF inhibitor together before (but taking only one type is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs (fluzoparib and apatinib) as maintenance therapy after chemotherapy for women with relapsed ovarian cancer. It might help keep the cancer from coming back for those who have already responded well to platinum-based chemo.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
This Phase 2 trial tests whether adding two medicines (fluzoparib plus apatinib) works better than fluzoparib alone to keep recurrent ovarian, fallopian tube, or primary peritoneal cancer from growing. It targets people whose cancer responded to recent platinum chemotherapy and who previously took a PARP inhibitor as maintenance therapy.
This trial tests whether taking fluzoparib (a PARP inhibitor) plus apatinib (a targeted therapy) after initial chemotherapy can help keep advanced ovarian, fallopian tube, or primary peritoneal cancer from coming back. It is for people who have finished their first treatment and are in good overall health.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
This trial tests a combination of two oral medications—fluzoparib (a PARP inhibitor) and famitinib (a TKI)—as maintenance therapy to keep advanced ovarian cancer from coming back after successful first-line chemotherapy. It is for women whose cancer responded well to initial platinum-based treatment.
Hear when a new Ovarian Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.